These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 14464072)

  • 21. Pharmacodynamic effects and clinical use of alpha methyldopa in the treatment of essential hypertension.
    ONESTI G; BREST AN; NOVACK P; MOYER JH
    Am J Cardiol; 1962 Jun; 9():863-7. PubMed ID: 14482028
    [No Abstract]   [Full Text] [Related]  

  • 22. Another hypotensive agent--methyldopa.
    DALEY D; EVANS B
    Br Med J; 1962 Jul; 2(5298):156-8. PubMed ID: 13883201
    [No Abstract]   [Full Text] [Related]  

  • 23. Methyldopa in the treatment of hypertension.
    BAYLISS RI; HARVEY-SMITH EA
    Lancet; 1962 Apr; 1(7233):763-8. PubMed ID: 13866047
    [No Abstract]   [Full Text] [Related]  

  • 24. Spontaneous formation of conjugates of alpha-methyl-DOPA and DOPA with serum proteins and experimental production of specific antibodies against these haptens.
    Cîrstea M; Suhaciu G; Cîrje M
    Physiologie; 1983; 20(1):3-10. PubMed ID: 6405406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of alpha methyl dopa and alpha methyl dopa hydrazine with L-dopa therapy.
    Mones RJ
    N Y State J Med; 1974 Jan; 74(1):47-51. PubMed ID: 4591989
    [No Abstract]   [Full Text] [Related]  

  • 26. 3-O-Methyldopa inhibits astrocyte-mediated dopaminergic neuroprotective effects of L-DOPA.
    Asanuma M; Miyazaki I
    BMC Neurosci; 2016 Jul; 17(1):52. PubMed ID: 27456338
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical trial of a new hypotensive drug, methyldopa ("aldomet").
    BAUMGARTEN A
    Med J Aust; 1962 Jul; 49(2)():52-5. PubMed ID: 13865946
    [No Abstract]   [Full Text] [Related]  

  • 28. Methyldopa in hypertension. Clinical and pharmacological studies.
    DOLLERY CT; HARINGTON M
    Lancet; 1962 Apr; 1(7233):759-63. PubMed ID: 13887051
    [No Abstract]   [Full Text] [Related]  

  • 29. DISSOCIATION OF THE DECARBOXYLASE-INHIBITING AND NOREPINEPHRINE-DEPLETING EFFECTS OF ALPHA-METHYL-DOPA, ALPHA-ETHYL-DOPA, 4-BROMO-3-HYDROXY-BENZYLOXYAMINE AND RELATED SUBSTANCES.
    LEVINE RJ; SJOERDSMA A
    J Pharmacol Exp Ther; 1964 Oct; 146():42-7. PubMed ID: 14221224
    [No Abstract]   [Full Text] [Related]  

  • 30. Synthesis of substituted DL-3(5-benzazolyl)alanines as dopa and alpha-methyldopa analogs and their effects on dopamine beta-hydroxylase, tyrosinase and diphenoloxidase.
    Loriga M; Paglietti G; Sparatore F; Pinna G; Sisini A
    Farmaco; 1992 Apr; 47(4):439-48. PubMed ID: 1388592
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Agranulocytosis with alpha methyl DOPA.
    HALLWRIGHT GP
    N Z Med J; 1962 Sep; 61():470-2. PubMed ID: 13952193
    [No Abstract]   [Full Text] [Related]  

  • 32. [CLINICAL EXPERIENCES WITH ALPHA-METHYL-DOPA, A DECARBOXYLASE INHIBITOR].
    RIPKA O
    Cas Lek Cesk; 1965 Feb; 104():173-5. PubMed ID: 14308252
    [No Abstract]   [Full Text] [Related]  

  • 33. NTP Toxicology and Carcinogenesis Studies of alpha-Methyldopa Sesquihydrate (CAS No. 41372-08-1) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1989 Mar; 348():1-184. PubMed ID: 12704436
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical evaluation of alpha methyl-dopa.
    SPERBER RJ; DEGRAFF AC
    Am Heart J; 1963 Feb; 65():275-6. PubMed ID: 13990064
    [No Abstract]   [Full Text] [Related]  

  • 35. [Febrile reaction ("drug fever") due to alpha-methyldopa].
    Kirchmair H; Huber H
    Wien Klin Wochenschr; 1965 Oct; 77(39):699-702. PubMed ID: 5865300
    [No Abstract]   [Full Text] [Related]  

  • 36. [Stability and dissociation constants of L-dopa and alpha-L-methyldopa].
    Lippold BC; Jaeger I
    Arch Pharm (Weinheim); 1973 Feb; 306(2):106-17. PubMed ID: 4694922
    [No Abstract]   [Full Text] [Related]  

  • 37. Intraocular pressure studies with alpha-methyl-dopa.
    LAIBSON PR; KRISHNAN ; LEOPOLD IH
    Arch Ophthalmol; 1962 Nov; 68():648-50. PubMed ID: 13928121
    [No Abstract]   [Full Text] [Related]  

  • 38. Spurious elevation of urinary catecholamines during therapy with alpha-methyl-dopa. A diagnostic pitfall.
    GIFFORD RW; TWEED DC
    JAMA; 1962 Oct; 182():493-5. PubMed ID: 13947776
    [No Abstract]   [Full Text] [Related]  

  • 39. [The use of the combination of L-alpha-methyldopa and dichlorothiazide in the treatment of arterial hypertension].
    BAILA MR; CINTAS JA
    Dia Med; 1962 Dec; 34():2422-4. PubMed ID: 13969004
    [No Abstract]   [Full Text] [Related]  

  • 40. [Facilitation of the effects of L-DOPA by alpha-methyldopa].
    Uspenskiĭ AE; Korobov NV
    Biull Eksp Biol Med; 1976 Mar; 81(3):314-6. PubMed ID: 986203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.